Silverarc Capital Management’s Krystal Biotech KRYS Stock Holding History

Silverarc Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,000	Closed	-$1.78M	–	79
2024 Q1	$1.78M	Buy	+10,000	New	+$1.39M	0.49%	51
2023 Q4	–	Sell	-71,531	Closed	-$8.3M	–	79
2023 Q3	$8.3M	Sell	71,531 -47,410	-40%	-$5.78M	2.52%	11
2023 Q2	$14M	Buy	118,941 +84,927	+250%	+$8.67M	4.32%	5
2023 Q1	$2.72M	Sell	34,014 -24,521	-42%	-$1.93M	1.12%	33
2022 Q4	$4.64M	Buy	58,535 +1,890	+3%	+$140K	1.33%	28
2022 Q3	$3.95M	Sell	56,645 -48,632	-46%	-$3.51M	1.34%	28
2022 Q2	$6.91M	Buy	105,277 +58,788	+126%	+$3.66M	2.13%	17
2022 Q1	$3.09M	Sell	46,489 -181	-0.4%	-$11.3K	1.28%	18
2021 Q4	$3.27M	Buy	+46,670	New	+$2.72M	1.32%	23

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Silverarc Capital Management's KRYS Position: Q2 2024 in Review

Silverarc Capital Management sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 10,000 shares — an estimated $1.78M sold.

Silverarc Capital Management first reported a position in KRYS in Q4 2021 and held it in 9 quarters. The position peaked at $14M in Q2 2023. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

Silverarc Capital Management reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
Silverarc Capital Management sold 10,000 Krystal Biotech shares in Q2 2024, an estimated $1.78M.
Silverarc Capital Management first reported a position in Krystal Biotech in Q4 2021 and held it in 9 quarters.
Silverarc Capital Management's Krystal Biotech position peaked at $14M in Q2 2023.
245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.